Entamoeba histolityca produces the monocyte locomotion inhibitory factor (MLIF), a pentapeptide with powerful anti-inflammatory properties. MLIF may regulate trauma-induced inflammation through the effects it exerts directly or indirectly on immune cells, modulating the production and/or expression of the cytokines involved in the inflammatory processes that occur after damage. The aim of the present study was to evaluate the effect of MLIF on production of pro/ anti-inflammatory cytokines after contusion in the rat tibia. Fifty-four Wistar rats were subjected to controlled contusion with a special guillotine-type device, and 36 rats were injected with MLIF or tenoxicam into the tibia. Eighteen animals received saline; the animals were sacrificed 24 or 48 hours after injection. Cytokine mRNA and protein production were determined by reverse transcriptasepolymerase chain reaction (RT-PCR), immunofluorescence, and hematoxylineosin staining was performed to visualize cellular infiltration in the rats' injured tissue. Expression levels of the cytokines interferon gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and transforming growth factor-beta (TGF-β) mRNA were inhibited significantly by MLIF at 24 hours postcontusion. MLIF significantly increased the expression levels of IL-10 at 24 hours compared with tenoxicam or the control group. These changes were associated with a significant decrease in protein production levels of TNF-α, IFN-γ, IL-6 and TGF-β at 24 hours. Histological evaluation showed the presence of infiltration by neutrophils, monocytes and leucocytes in control tissues. This infiltration was decreased after MLIF administration, and intense infiltration was observed in tenoxicam-treated group. MLIF inhibited the expression of pro-inflammatory cytokines and increased the expression of anti-inflammatory cytokine IL-10.
properties. 5 Such an effect may be attributable to the chemical activity of the peptide. Ongoing quantum chemistry studies have revealed that a pharmacophore group in the MLIF sequence (Cys-Asn-Ser) could be responsible for most of the anti-inflammatory properties of the molecule. 6 It has also been reported that analogues of MLIF (Tyr-Cys-Ans-Ser and His-Cys-Ans-Ser) have neuroprotective effects in a mouse model of focal ischemia-reperfusion injury. 7 The selective actions of MLIF upon a variety of cell types suggest that it disrupts the pro-and anti-inflammatory networks. 1, 6, 8 Inflammation plays an important role in the healing process.
Traumatic muscle injury triggers a cascade of inflammatory responses that are believed to contribute to the pathogenesis of secondary bruising. 9 These inflammatory responses include the activation of and infiltration by neutrophils and macrophages, as well as the upregulation of adhesion molecules and cytokines. Tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and IL-1β are the major pro-inflammatory cytokines involved in post-traumatic inflammatory responses. 10 -13 Elevated levels of these cytokines have been detected in the serum of patients with severe muscle injuries, and it has been demonstrated that contusion induces a release of cytokines that are constitutively present in damaged and inflammatory cells in the vicinity of the trauma. 14 Little is known about the potential role of MLIF in the regulation of these cytokines in human muscle injury, but evidence from animal studies suggests that the presence of TNF-α, IL-6 or IL-1β in the initial post-injury period is harmful, and suppression of acute surges of these cytokines may reduce muscle damage and improve the functional outcome. 15 The purpose of this study was to evaluate the effect of MLIF on cytokine expression during inflammation caused by the early events during muscle damage in a rat model.
| MATERIALS AND METHODS
The monocyte locomotion inhibitory factor (MLIF) (MetGln-Cys-Asn-Ser) was obtained commercially (96% pure, American Peptide Co., Sunnyvale, CA, USA 
| EXPERIMENTAL DESIGN
Fifty-four male Wistar rats of 280-300 g were obtained from Faculty of Medicine UNAM (México City, México), IL-10  5′-ACCAATGGTGTCCTTTCACTTGCC-3′  5′-GCGCTGAGCTGTTGCAAGGATAAT-3′  132   IL-6  5 ′-TGTGGAAGACAAACCATGTTGCCG-3′  5′-TATTGCAGGTGAGCTGGACGTTCT-3′  117   IFN-γ  5′-CAACCAGGCCATCAGCAACAACAT-3′  5′-TCTGTGGGTTGTTCACCTCGAACT-3′  128   TGF-β  5′-AGACGGAATACAGGGCTTTCGCTT-3′  5′-TCGACGTTTGGGACTGATCCCATT-3′  100   TNF-α  5′-CTCTTCTGTCTACTG AACTTCGGG-3′  5′-GAGAAGATGATCTGAGTGTGAGGG-3′  115   HPRT  5′-GAACTAGCAGACGTTCTAGTCCTG-3′  5′-GATCTGTCTGTC TCACAAGGGAAG-3′  185 IL-10: interleukin-10; IL-6: interleukin-6; Interferon-gamma: IFN-γ; TGF-β: transforming growth factor-beta; TNF-α: tumour necrosis factor-alpha; HPRT: hypoxanthine phosphoribosyltransferase; PCR: polymerase chain reaction.
F I G U R E 2
Expression of pro-inflammatory cytokines after application of the monocyte locomotion inhibitory factor (MLIF) or tenoxicam post-trauma. The expression of IFN-γ, TNF-α and hypoxanthine phosphoribosyltransferase (HPRT) genes was determined using reverse transcriptase-polymerase chain reaction with RNA isolated from injured muscle. Samples were harvested at 24 and 48 h after injury. A, IFN-γ mRNA expression was significantly inhibited by tenoxicam at 24 h; this inhibition was stronger in response to MLIF at 24 h; B, TNF-α mRNA expression was significantly lower in the group treated with tenoxicam at 24 and 48 h compared to the control group. Nevertheless, the expression of TNF-α mRNA was strongly inhibited by MLIF at 24 h compared to both the control group and the tenoxicam group. The values represent the means ± standard deviation, n = 18 (6 rats were used for the treatment with MLIF, 6 rats for the treatment with tenoxicam and 6 control rats for determination of expression of cytokines by RT-PCR), *P < 0.001, **P < 0.0001 (Mann-Whitney test), Bp = Base pairs F I G U R E 3 Effect of the monocyte locomotion inhibitory factor (MLIF) on mRNA expression levels of IL6 and TGF-β. 24 and 48 h after the application of MLIF or tenoxicam in the rat injury model, we determined in situ the expression of IL-6 and TGF-β mRNA using RT-PCR: (A) unlike tenoxicam, MLIF strongly inhibited the expression of IL-6 at the 2 tested times; B, TGF-β mRNA expression was significantly inhibited by MLIF, compared to the tenoxicam or control groups at 24 and 48 h. The values represent means ± standard deviation. *P < 0.001, **P < 0.0001 (Mann-Whitney test)
with permission of the Ethics Committee of the University. Standardized contusions were produced according to the method proposed by An et al 16 using a guillotine device developed to produce simple fractures. We adjusted the guillotine travel distance to 2 mm to produce a controlled contusion. The rats were anesthetized with a mixture of ketamine (60 mg/kg) and xylazine (10 mg/kg/i.m.) (Darwin Laboratories, México City, México). Briefly, a 400-g weight was dropped from a 25-cm height and travelled a distance of 2 mm to produce a contusion in the right tibia of rats in all groups. To verify that there were no fractures present; radiographs were taken following the contusion (Figure 1 ). After injury, the animals were randomly distributed into 3 groups according to drug administration (n = 18 rats per group): rats in group 1 were administered a saline solution and were used as control; rats in group 2 were injected with tenoxicam, a non-steroidal anti-inflammatory drug (NSAID; 10 mg/kg/i.m. per day); and rats in group 3 were injected with MLIF (50 ng/kg/i.m. per day).
The optimal concentration of MLIF and tenoxicam was obtained using a dose-response curve.
| Immunofluorescence
Twenty-four and 48 hours after the contusion and the administration of drugs, a lethal dose of sodium pentobarbital (65 mg/kg) was administered to animals from each group (n = 6 for 24 hours and n = 6 for 48 hours). goat IgG-CFL647:sc-516244), respectively (Santa Cruz Biotech) were used at a 1:200 dilution, followed by incubation for 2 hours. The slides were then washed with PBT solution, stained with propidium iodide and coverslipped in Vecta-shield mounting medium (Vector Laboratories, Burlingame, CA, USA). All sections were observed and photographed using a fluorescence microscope (Olympus, Optical sectioning microscopy attached to an Axioplan imaging Apotome apparatus, Zeiss, AxioVision, Gottingen, Germany) using a suitable filter set ( Red and fuchsia). The images were captured at 1500× magnification with oil immersion. Ten slide were reviewed for each cytokine studied, 10 fields were counted from each slide, a minimum of 50 cells was quantified per field.
| Analysis of TGF-β, TNF-α, IFN-γ, IL-6
and IL-10 mRNA expression by real-time reverse transcriptase-polymerase chain reaction
Total RNA was extracted from soft tissue using TRIzol reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA). The quality and quantity of total RNA were assessed by measuring the absorbance ratios of total RNA at 260/280 and F I G U R E 4 Expression of anti-inflammatory cytokine IL-10.
Post-injury and post-administration of the monocyte locomotion inhibitory factor (MLIF) or tenoxicam, we determined in situ the expression of interleukin-10 (IL-10) mRNA by reverse transcriptasepolymerase chain reaction using samples of injured tissue at 24 and 48 h. IL-10 was expressed in the rats treated with MLIF at both treatment times and was more strongly expressed at 48 h compared with the control or tenoxicam groups. The values represent means ± standard deviation. *P < 0.001, **P < 0.0001 (MannWhitney test) 260/230 nm using the NanoDrop-2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). Primer sequences for TGF-β, TNF-α, IFN-γ, IL-6, IL-10, and the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT) were designed (Table 1) . Real-time PCR was performed with FastStart Universal Power SYBR Green Master Mix (ROX) (Roche Diagnostics, Indianapolis, IN, USA) using the 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). In brief, 1 μL of cDNA was added to a PCR mix consisting of 10.5 μL of FastStart SYBR green master mix, 11 μL of RNase-free water and 1 μL of each primer ( Table 1 ). The real-time PCR running protocol was 10 minutes at 95°C, followed by 40 cycles of 95°C for 10 seconds and 60°C for 1 min. The dissociation curves were obtained by heating from 60 to 95°C. For data analysis, StepOne version 2.0.2 software (Applied Biosystems) was used to calculate the levels of target gene expression in samples, relative to the expression level in control samples, using the comparative cycle threshold method (ΔΔCT) 17 with normalization to HPRT mRNA level in each sample. Images were captured using commercially available image analysis software (Mocha; Jandel Scientific, San Rafael, CA, USA).
| Hematoxylin and eosin staining
Three animals from each group were anesthetized and sacrificed at 24 or 48 hours after injury. The traumatized extremities were disarticulated at the knee level. Injured soft tissue specimens were dissected, fixed in 4% paraformaldehyde solution, prepared as thin (3 μm in thickness) sections and stained with hematoxylin and eosin (H & E) using standard histological procedures. Histological analysis was performed using light microscopy.
| Statistical analysis
Data were obtained from 6 independent experiments and analysed using SPSS 15 for Windows (SPSS, Chicago, IL, USA). Values are presented as the mean ± standard deviation (SD). Statistical test analysis of variance (ANOVA) and the Mann-Whitney U-test were used for multiple comparisons, and P < 0.05 was considered statistically significant.
| RESULTS

| MLIF treatment inhibits proinflammatory cytokine mRNA expression
IFN-γ mRNA expression was significantly inhibited (2%, P < 0.0001) in the group treated with MLIF compared with the group treated with tenoxicam (5%, P < 0.001) or the control group (9.8%) at 24 hours post-injury (Figure 2 ). TNF-α mRNA expression was significantly inhibited (−18%, −12%, **P < 0.0001) at 24 and 48 hours after contusion in the rats treated with MLIF. In the group treated with F I G U R E 5 Effect of the monocyte locomotion inhibitory factor (MLIF) on cytokine protein expression in rats after contusion. The rats were treated with MLIF, tenoxicam or saline, as described in Methods. The Samples were double-stained with monoclonal antibodies against IFN-γ, TNF-α, IL-6, IL-10 or TGF-β. The images of damaged muscle areas were captured at 1500 × magnification with oil immersion. In (A and B) , immunostained cytokines are shown in red, yellow or green, and in (C) the histograms represent the control (white), tenoxicam-treated groups (dotted 24 h, vertical lines 48 h), and MLIF (diagonals 24 h, black 48 h). Values are presented as the mean ± standard deviation; n = 18 (6 rats were used for the treatment with MLIF, 6 rats for the treatment with tenoxicam and 6 control rats for the determination of expression of cytokines by immunofluorescence), *P < 0.05 tenoxicam, TNF-α mRNA expression was significantly lower (2% and 4% and *P < 0.001 and **P < 0.0001, respectively) after 24 and 48 hours (Figure 2 ). IL-6 mRNA expression was strongly inhibited at 24 hours post-injury in the group treated with MLIF (−3%; P < 0.0001) compared with the group treated with tenoxicam (5%, P < 0.001) (Figure 3 ). In addition, the data presented in Figure 3 show significant inhibition of TGF-β mRNA after treatment with MLIF at 24 and 48 hours post-injury (2%, 3%, respectively, P < 0.001). In contrast, the values obtained for the group treated with tenoxicam at the same times were not significantly different (NS) compared with the MLIF or control groups (Figure 3 ). IL-10 mRNA expression was significantly increased in rats treated with MLIF at 24 hours (13%, P < 0.001) and strongly increased after 48 hours (21%, P < 0.0001) (Figure 4) . Expression of IL-10 mRNA was significantly inhibited in the groups treated with tenoxicam at 24 and 48 hours (2%, 5%, respectively, P < 0.001).
| Monocyte locomotion inhibitory factor treatment decreases protein expression levels for TNF-α, IFN-γ, TGF-β and IL-6 cytokines and increases IL-10 expression
The protein levels of pro-and anti-inflammatory cytokines were measured in situ by immunofluorescence 24 and 48 hours after experimental contusion in rat tibia. TNF-α, IFN-γ, IL-6 and TGF-β protein expression was inhibited in the groups treated with MLIF (24%, 20%, 19% and 43% at 24 hours) compared with the group treated with tenoxicam (71%, 89%, 83%, 97%, respectively, at 24 hours) or the control group (94%, 87%, 86%, 86%, respectively, at 24 hours) ( Figure 5 ). IL-10 production was significantly increased in the groups treated with MLIF (100% P < 0.05) in contrast to the groups treated with tenoxicam, which showed decreased IL-10 expression at 24 hours (29%) ( Figure 5 ).
| Histological analysis
H and E staining is shown in Figure 6 and Table 2 . Polymorphonuclear neutrophils (PMNs), monocytes and leucocytes were predominant in cellular infiltrates in animals from the control group at 24 and 48 hours. Moderate inflammatory infiltration by PMNs, lymphocytes and histiocytes was detected in tenoxicam-or MLIF-treated groups at 24 hours. Intense predominance of histiocytes and eosinophils in the inflammatory infiltrate was observed in the tenoxicam-treated group, while predominance of PMNs and histiocytes was detected around the muscle fibres from MLIF-treated animals at 48 hours. Macroscopic analysis (Table 2) : severe interstitial edema, vascular congestion and muscle necrosis were observed in the control group. Moderate edema and vascular congestion were observed in MLIF-or tenoxicam-treated groups, necrotic muscle fibres were observed in all groups at 24 and 48 hours ( Figure 6 and Table 2 ).
| DISCUSSION
MLIF is an anti-inflammatory oligopeptide produced by E. histolytica, 18 which exhibits potent anti-inflammatory activities both in vitro and in vivo. 4, 19 Published research also suggests that activation of NF-kB and MAPK signalling pathways by MLIF may alter expression of molecules involved in immune responses, such as inflammation. 3 Contusion or injury leads to rapid infiltration of the muscle by inflammatory cells, such as monocytes, neutrophils and macrophages, which produce proinflammatory cytokines (TNF-α, IL-1β, IL-6). 20 Our findings show that PMNs, monocytes and leucocytes are the predominant inflammatory cells in the control group, and they are decreased in the groups treated with MLIF or tenoxicam. We observed a less-pronounced infiltration of inflammatory cells in the group treated with MLIF at 24 hours, confirming the inhibitory effect on monocyte infiltration and consequent expression of inflammatory cytokines. MLIF significantly reduced TNF-α, IFN-γ, IL-6 and TGF-β mRNA transcription in situ and protein synthesis post-contusion in rat tibia. TNF-α and IL-1β are early regulators of the immune response and both induce a release of cytokines, such as IL-6 and IL-8. The expression of IL-6 was remarkably inhibited in rats treated with MLIF. This effect may be related to the fact that IL-6 produces greater damage to soft tissue. Studies have revealed that IL-6 has a temporary effect following moderate trauma, and the levels of the cytokine are low during the end of the healing . The data represents the mean ± SD, n = 6 rats were used for each treatment. *P < 0.001, **P < 0.02, ***P < 0.03 Control vs tenoxicam and MLIF.
process. 21 Decreased TNF-α levels enhance muscle recovery and function at later stages. 22, 23 However, it has been reported that when TNF-α activity is reduced or inhibited by TNF blockers, muscle and joint injuries are reduced as the intensity of the inflammatory process is repressed and as the disease progression changes. Additionally, Yao et al 7 reported that the pharmacophore group of MLIF and MLIF analogues markedly reduces the levels of pro-inflammatory cytokines, such as IL-1β and TNF-α, after ischemia. In addition, both local and systemic levels of TGF-β increase during the muscle healing process post-contusion. These results indicate that MLIF reduces production of TGF-β. This finding is particularly interesting because a decrease in TGF-β levels reduces fibrosis formation and favours muscle healing.
MLIF reduced the expression of IFN-γ at 24 hours, but not at 48 hours, possibly because IFN-γ is a powerful antifibrotic agent that aids muscle healing process following an injury. Foster et al, 24 using a mouse laceration model, observed that fibrotic area is reduced following injection of IFN-γ after an injury. Additionally, IFN-γ inhibits the synthesis of collagen by fibroblasts, and endogenous IFN-γ can negatively regulate the TGF-β signalling pathway during wound healing. 25 -27 This intricate cytokine network is primarily regulated by IL-10. Identification of IL-10 as a sensitive biomarker of injury at 24 hours suggests the importance of a compensatory anti-inflammatory response generated by muscle injury. Thereby, MLIF can negatively modulate the process of wound healing by suppression of the production of IFN-γ. As IL-10 can inhibit IFN-γ F I G U R E 7 Possible mechanism of action of the MLIF on Pro/anti-inflammatory cytokines. It is probable that MILF generates a signalling cascade, which finally activates transcription factors such as nuclear factor κB (NF-κB); after its translocation into the nucleus, it binds to sites regulating a large number of cytokine production-implicated genes. In this way, after the soft tissue injury can be established, first an acute transitory reaction involving pro-inflammatory cytokines, followed by an increase and dominant pattern of anti-inflammatory signals mainly through the increase in interleukin-10 production and its receptor expression, both cytokines can antagonize one another. Thus, IFN-γ signal transduction pathway blockade by MLIF may enhance IL-10 production and IL-10 signalling in a positive feedback manner and may be an important strategy for accelerating the muscle healing process. Tenoxicam (an NSAID) is commonly prescribed for the treatment of musculoskeletal injuries.
Tenoxicam has been reported to cause adverse effects, such as gastrointestinal damage, renal failure, asthma and heart disease 28, 29 ; thus, the development of alternative antiinflammatory agents with fewer adverse effects is much needed. It has been shown that MLIF does not induce cell damage or cytotoxic effects, it does not affect cell apoptosis (MLIF down-regulates Fas receptor, and it does not activate caspase-3 or cause the release of cytochrome-C) or lead to necrosis (Figure 7) . 30 This study shows that the effect of MLIF on pro-inflammatory cytokines IFN-γ, TNF-α and IL-6 was stronger than that caused by tenoxicam. The precise mechanisms that MLIF uses to cause these biological effects are unknown; however, it is known that MLIF interacts with human leucocytes by means of a mannose-containing receptor and that it causes an increase in the number of pericentriolar microtubules, as well as in cytoplasmic AMPc concentration, without concomitant GMPc diminution. The p65-p50 heterodimer comprises the most abundant form of NF-κB in a PMA-induced system. Temporary studies showed that MLIF induces p50 translocation; this can also be explained by the fact that MLIF induces AMPc synthesis and protein kinase A phosphorylation ( Figure 7) . 31, 32 It has been reported that MLIF can affect NF-kB-regulated gene expression, and this may contribute to their anti-inflammatory effects. 18 The effect of MLIF unraveled in this study is the inhibition of pro-inflammatory cytokines, such as TNF-α, IFN-γ and IL-6, and increased expression of IL-10 anti-inflammatory cytokine, which may contribute to the immune-protective effect in the state of acute post-traumatic response in rats. Further studies are needed to elucidate the role played by cytokines, specifically, TGF-β, in the pathogenesis of contusion-induced trauma.
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